Skip to main content
. Author manuscript; available in PMC: 2015 Jan 20.
Published in final edited form as: Diabetes. 2007 Feb 7;56(5):1341–1349. doi: 10.2337/db06-1619

TABLE 2.

Effect of AMP-DNM on ceramide and glucosylceramide content of liver and muscle of ob/ob and normal C57Bl/6J mice

GlcCer (nmol/mg protein) Cer (nmol/mg protein)
Liver
 Normal: 0 mg AMP-DNM 2.12 ± 0.15 9.44 ± 0.82
 Normal: 25 mg AMP-DNM 1.24 ± 0.09* 10.31 ± 0.96
 ob/ob: 0 mg AMP-DNM 3.81 ± 0.24 102.6 ± 12.3
 ob/ob: 25 mg AMP-DNM 2.24 ± 0.14* 95.9 ± 11.6
Muscle
 Normal: 0 mg AMP-DNM 1.48 ± 0.31 1.42 ± 0.60
 Normal: 25 mg AMP-DNM 0.89 ± 0.22* 1.47 ± 0.22
 ob/ob: 0 mg AMP-DNM 2.49 ± 0.41 1.21 ± 0.31
 ob/ob: 25 mg AMP-DNM 1.41 ± 0.16* 1.29 ± 0.24

Data are means ± SD. Animals were fed for 2 weeks with 0 or 25 mg AMP-DNM/kg. Liver and muscle tissue were collected and analyzed on ceramide and glucosylceramide content by HPLC-based procedures described in research design and methods. Values represent the mean of four animals.

*

P < 0.05 by Student’s t test (0 vs. 25 mg treatment group).

Cer, ceramide; GlcCer, glucosylceramide-to-ceramide ratio.